Mark Redell, Miguel Sierra-Hoffman, Maha Assi, Markian Bochan, David Chansolme, Anurag Gandhi, Kathleen Sheridan, Ivan Soosaipillai, Thomas Walsh, Jill Massey
BACKGROUND: Oritavancin (ORI) is a long-acting lipoglycopeptide indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible Gram-positive (GP) pathogens. METHODS: Data collected from a retrospective observational program (2014-2017), Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME), describe the utilization, outcomes, and adverse events (AEs) associated with ORI in 440 patients treated at 26 US sites for ABSSSI and other GP infections...
November 2019: Open Forum Infectious Diseases